Sechenov School
Home › Pharmacology › Non-CYP Enzymes and Genetic Polymorphism

Non-CYP Enzymes and Genetic Polymorphism

For medical students2 min readUpdated 2026-10-10

Genetic polymorphisms in non-cytochrome P450 enzymes directly determine individual rates and safety of drug metabolism for several critical medications. Hereditary mutations in the genes encoding these enzymes lead to a sharp increase in the incidence of severe adverse drug reactions due to an altered physiological response to standard dosages.

PolymorphismDetermines the patient's individual clinical response to pharmacotherapy.
LiverThe primary site of localization of N-acetyltransferase.
ErythrocytesThe main target of damage in glucose-6-phosphate dehydrogenase deficiency.
PrevalenceUp to 50% of individuals of European descent exhibit the slow acetylator phenotype.

The "Slow Acetylator" Phenotype (N-Acetyltransferase Deficiency)

One of the most striking examples of genetic polymorphism is the variability in hepatic N-acetyltransferase activity. This enzyme is responsible for the metabolism of xenobiotics and drugs via acetylation reactions.

In clinical practice, a significant group of patients exhibit a congenital deficiency of this enzyme, commonly referred to as "slow acetylators". The main pharmacological problem associated with this phenotype is that reduced enzyme activity leads to a critical delay in drug elimination. Consequently, standard therapeutic doses can become toxic, resulting in a dramatic increase in adverse drug reactions.

Major offending agents metabolized via this pathway include:

Epidemiologically, the slow acetylator status is highly prevalent among populations of European descent, affecting up to 50% of individuals in this group.

Hemolytic Anemia in Glucose-6-Phosphate Dehydrogenase Deficiency

Another critically important non-CYP enzyme is glucose-6-phosphate dehydrogenase (G6PD), which is localized in erythrocytes. In the presence of a genetic deficiency of this enzyme, the administration of certain drugs triggers a specific pathogenic cascade.

The basis of pathogenesis is the formation of toxic quinone species that directly affect red blood cells. This leads to massive destruction (hemolysis) of erythrocytes and the rapid development of severe hemolytic anemia.

Life-threatening hemolytic episodes can be triggered by the following medications:

  1. Antimalarial alkaloids: quinine (Chininum) and quinidine;
  2. Sulfonamide drugs (Sulfanilamidea);
  3. The antibiotic chloramphenicol (Chloramphenicolum).

This genetic anomaly shows a strong geographic distribution, occurring most frequently among residents of tropical and subtropical regions worldwide, where the number of mutation carriers reaches 100 million.

Prolonged Apnea: Plasma Pseudocholinesterase Deficiency

A third major example of polymorphism involves plasma pseudocholinesterase (butyrylcholinesterase). This enzyme plays a key role in the inactivation of depolarizing neuromuscular blockers, specifically succinylcholine (Suxamethonium).

In patients with normal pseudocholinesterase activity, the duration of muscle relaxation following succinylcholine administration is only 5–7 minutes. However, individuals with a genetic deficiency of this enzyme experience a dangerous prolongation of neuromuscular blockade, lasting from 6 to 8 hours. During this period, the patient exhibits persistent apnea (cessation of breathing), requiring prolonged mechanical ventilation.

Epidemiologically, plasma pseudocholinesterase deficiency is extremely rare among populations of European descent (approximately 0.04%), but is significantly more frequent in specific ethnic groups, such as Alaskan Inuit populations (up to 1%).

Mnemonic

To remember the drugs that trigger hemolysis in G6PD deficiency, use the mnemonic QQSC: Quinine, Quinidine, Sulfonamides, Chloramphenicol.

Frequently asked questions

Which non-CYP enzymes exhibit clinically significant genetic polymorphisms?

Clinically significant genetic polymorphisms are found in the following non-CYP enzymes:

  • N-acetyltransferase — a hepatic enzyme whose deficiency leads to the "slow acetylator" phenotype.
  • Glucose-6-phosphate dehydrogenase — an erythrocyte enzyme whose deficiency causes hemolytic anemia.
  • Pseudocholinesterase — a plasma enzyme whose deficiency prolongs neuromuscular blockade.
  • Dihydropyrimidine dehydrogenase — an enzyme associated with toxicity from pyrimidine analogues.
  • Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) — an enzyme whose polymorphism is linked to irinotecan toxicity.
Which drugs are metabolized by hepatic N-acetyltransferase?

Drugs metabolized by hepatic N-acetyltransferase include:

  • Isoniazid (Isoniazidum).
  • Sulfonamides.
  • Procainamide (Procainamidum).
What specific adverse effects develop in slow acetylators taking isoniazid?

Slow acetylators taking isoniazid develop specific neurotoxic adverse effects related to vitamin B6 (pyridoxine) depletion:

  • Peripheral neuropathy — neuritis occurring due to impaired pyridoxal phosphate synthesis.
  • Central nervous system toxicity — manifesting as memory loss, psychoses, and seizures.

The risk of these effects is driven by delayed drug elimination, a 4- to 6-fold increase in plasma concentration, and systemic drug accumulation.

Which medications trigger erythrocyte hemolysis in G6PD deficiency?

Erythrocyte hemolysis in G6PD deficiency is triggered by:

  • Quinine (Chininum) and quinidine.
  • Sulfonamides (Sulfanilamidea).
  • Chloramphenicol (Chloramphenicolum).
  • Primaquine.
  • Acetaminophen (Paracetamol).
What is the biochemical mechanism of erythrocyte destruction in G6PD deficiency?

The biochemical mechanism of erythrocyte destruction stems from impaired function of the pentose phosphate pathway and decreased NADPH production. Due to a lack of NADPH, glutathione reductase fails to maintain adequate levels of reduced glutathione. As a result, reactive oxygen species oxidize the sulfhydryl (-SH) groups of hemoglobin. This causes disulfide bond formation and hemoglobin aggregation, leading to the formation of Heinz bodies. These inclusions damage the erythrocyte membrane, ultimately resulting in hemolysis and hemolytic anemia.

What are the clinical risks of being a "slow acetylator"?

Slow acetylators experience delayed elimination of drugs such as isoniazid and procainamide, leading to drug accumulation and a sharply increased risk of adverse toxic effects.

Why does prolonged apnea occur after administering succinylcholine?

The cause is a congenital deficiency of plasma pseudocholinesterase. Due to insufficient enzyme activity, muscle relaxation is prolonged from the normal 5–7 minutes to 6–8 hours.

In which regions is glucose-6-phosphate dehydrogenase deficiency most prevalent?

This condition is most commonly found in residents of tropical and subtropical regions, affecting up to 100 million people globally.

Go deeper

More topics in Pharmacology

AnticoagulantsAtenololIrbesartanNeostigmineRibavirinSelective Norepinephrine Reuptake InhibitorsAntigout MedicationsNondepolarizing Neuromuscular BlockersBeta-Lactamase Inhibitor PenicillinsImmunofanAntiseptics Reference GuideEffects of Steroid HormonesPharmacology →